Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q2- Text added to 2022 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
AbbVie, abrocitinib, auremolimab, biotech, CIBINQO, excise, exempt, extremely, IRA, lichen, mucosal, notified, PBM, purple, regular, Republic, RINVOQ, unfavorable, upadacitinib, women
Removed:
delivered, lt, opt, passage, pharmacology, pre, profit, taxation, topMIND
Valuein 2022 Q2 filing- Value in 2022 Q3 filing
Original filings
Filing view